Discussion In this phase 2 tuberculosis clinical trial, an investigational intensive phase regimen comprised of daily low-dose rifapentine plus moxifloxacin in addition to isoniazid and pyrazinamide was not less bactericidal than the control regimen as assessed using sputum culture-based surrogate endpoints, and there was a possible trend towards superiority of the investigational regimen when MGIT liquid medium was used for endpoint measurement.
← all excerpts
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
1
—
—